Patient satisfaction with the benefits of overactive bladder treatment: Exploration of influencing factors and development of a satisfaction assessment instrument

Neurourology and Urodynamics

Volumn 30, Issue 1, 2011, Pages 62-68

  Zinner, Norman ^a   Kobashi, Kathleen ^b   Koochaki, Patricia ^c   Fix, Deborah ^c   Egermark, Mathias ^d  

^a Western Clinical Research   (United States)

^b VIRGINIA MASON MEDICAL CENTER   (United States)

^c PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

antimuscarinic; darifenacin; overactive bladder (OAB); patient satisfaction; treatment outcomes

Indexed keywords

DARIFENACIN;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; FEMALE; HUMAN; OVERACTIVE BLADDER; PATIENT SATISFACTION; STRUCTURED INTERVIEW; STRUCTURED QUESTIONNAIRE;

AGED; AGED, 80 AND OVER; BENZOFURANS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PATIENT SATISFACTION; PYRROLIDINES; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE;

EID: 78651099279     PISSN: 07332467     EISSN: 15206777     Source Type: Journal    
DOI: 10.1002/nau.20890     Document Type: Article

References (16)

1. Coyne KS, Sexton CC, Irwin DE, et al. 2008. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: Results from the EPIC study. BJU Int 101: 1388-95.
2. Donovan A, Bosch R, Gotoh M, et al. Symptom and quality of life assessment. In:, Abrams P, Cardozo L, Khoury S, Wein A, editors. Incontinence. Book 1. Basics and evaluation. International Continence Society; 2005.
3. Atkinson MJ, Sinha A, Hass SL, et al. 2004. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2: 12.
4. Burgio KL, Goode PS, Richter HE, et al. 2006. Global ratings of patient satisfaction and perceptions of improvement with treatment for urinary incontinence: Validation of three global patient ratings. Neurourol Urodyn 25: 411-7.
5. Piault E, Evans CJ, Espindle D, et al. 2008. Development and validation of the Overactive Bladder Satisfaction (OAB-S) Questionnaire. Neurourol Urodyn 27: 179-90.
6. Zinner N, Kobashi KC, Ebinger U, et al. 2008. Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy. Int J Clin Pract 62: 1664-74.
7. Coyne KS, Matza LS, Kopp Z, et al. 2006. The validation of the patient perception of bladder condition (PPBC): A single-item global measure for patients with overactive bladder. Eur Urol 49: 1079-86.
8. Choo MS, Doo CK, Lee KS, 2008. Satisfaction with tolterodine: Assessing symptom-specific patient-reported goal achievement in the treatment of overactive bladder in female patients (STARGATE study). Int J Clin Pract 62: 191-6.
9. Harding G, Coyne KS, Thompson CL, et al. 2008. The responsiveness of the uterine fibroid symptom and health-related quality of life questionnaire (UFS-QOL). Health Qual Life Outcomes 6: 99.
10. Chang H, Han DH, Mo JH, et al. 2009. Early compliance and efficacy of sublingual immunotherapy in patients with allergic rhinitis for house dust mites. Clin Exp Otorhinolaryngol 2: 136-40.
11. Koga T, Matsuse H, Kohrogi H, et al. 2007. Impact of nasal condition on self-assessed disease control and treatment satisfaction in patients with asthma complicated by allergic rhinitis. Allergol Int 56: 427-31.
12. Abrams P, Kelleher C, Huels J, et al. 2008. Clinical relevance of health-related quality of life outcomes with darifenacin. BJU Int 102: 208-13.
13. FitzGerald MP, Lemack G, Wheeler T, et al. 2008. Nocturia, nocturnal incontinence prevalence, and response to anticholinergic and behavioral therapy. Int Urogynecol J Pelvic Floor Dysfunct 19: 1545-50.
14. Khullar V, Chapple C, Gabriel Z, et al. 2006. The effects of antimuscarinics on health-related quality of life in overactive bladder: A systematic review and meta-analysis. Urology 68: 38-48.
15. Michel MC, Oelke M, Goepel M, et al. 2007. Relationships among symptoms, bother, and treatment satisfaction in overactive bladder patients. Neurourol Urodyn 26: 190-5.
16. Bolge SC, McDonnell DD, Chen A, et al. 2007. Patient satisfaction with extended release tolterodine or oxybutynin in overactive bladder. Curr Med Res Opin 23: 1903-12.